Our Pricing

Wegovy Discount Code UK: How to Save on Semaglutide Weight Loss Treatment

Published on: June 03, 2026

Searching for a wegovy discount code uk online that actually works? At Cured Pharmacy, use code WEIGHTLOSSNEW to access genuine UK-licensed Wegovy from £79.00, with transparent pricing shown before your free clinical consultation. Our UK-registered prescribers assess your suitability in under 3 minutes, and all orders include discreet next-day delivery across the UK.

How the Wegovy Discount Code WEIGHTLOSSNEW Works

The discount code WEIGHTLOSSNEW is automatically applied at checkout when you complete your clinical assessment at Cured Pharmacy. Unlike promotional codes that exclude prescription medicines, this offer applies directly to your Wegovy prescription, reducing the starting price to £79.00 for eligible patients. Your final price depends on the dose your UK prescriber determines is appropriate based on your medical history and weight loss goals.

All Wegovy prescriptions at Cured Pharmacy require a free online consultation with a UK-registered prescriber, as semaglutide is a prescription-only medication regulated by the MHRA. Our transparent pricing model means you'll see the exact cost before completing your assessment — no hidden fees, no surprise charges at checkout. Superintendent pharmacist Tarun Kumar (GPhC 2233073) personally oversees all dispensing to ensure you receive genuine UK-licensed medication.

Clinical Evidence: How Wegovy Produces Weight Loss Results

The STEP clinical trial programme enrolled over 4,500 participants across multiple studies, providing robust evidence for semaglutide's efficacy in weight management [1]. Participants in STEP 1 who received the full 2.4mg maintenance dose experienced significant improvements not just in weight, but also in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers [2].

What makes these results particularly significant is the trial duration — 68 weeks represents genuine long-term data, not short-term water weight fluctuations. The STEP trials also demonstrated that weight loss continued progressively throughout the treatment period, with the greatest reductions occurring between weeks 20 and 60 [1]. Your UK prescriber will discuss realistic timelines during your consultation, as individual results vary based on starting weight, adherence, and lifestyle factors.

The STEP Trial Programme

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating. In the landmark STEP 1 trial, participants using semaglutide 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. The medication works by reducing appetite, slowing gastric emptying, and improving blood sugar regulation — three mechanisms that work together to create sustainable weight loss when combined with lifestyle modifications.

Wegovy vs Other Weight Loss Treatments Available in the UK

The UK weight loss treatment landscape has expanded significantly since the MHRA licensed semaglutide for obesity management in 2023. While Wegovy remains the most prescribed injectable GLP-1 treatment at Cured Pharmacy, understanding how it compares to alternatives helps you make an informed choice during your clinical assessment.

Semaglutide-based treatments like Wegovy work through a single GLP-1 pathway, whereas newer dual-action medications target both GLP-1 and GIP receptors. Oral medications like orlistat work through an entirely different mechanism — blocking fat absorption in the digestive system rather than affecting appetite hormones. Your prescriber will recommend the most appropriate treatment based on your medical history, previous weight loss attempts, and any contraindications in your health profile.

Injectable treatments require weekly self-administration using pre-filled pens, which most patients find straightforward after the first dose. The injection uses a very fine needle inserted subcutaneously into the abdomen, thigh, or upper arm. Cured Pharmacy provides detailed administration guidance with every prescription, and our clinical team remains available via phone on (+44) 116 4646009 if you have questions about technique or storage.

Wegovy Dosing Schedule and What to Expect

Most patients begin noticing appetite reduction within the first two weeks of treatment, even at the lowest 0.25mg starting dose. However, clinically significant weight loss typically becomes evident around week 8-12, once you've reached the 1.0mg or 1.7mg doses [1]. The full therapeutic effect manifests after several months at the 2.4mg maintenance dose, which is why the STEP trials measured outcomes at 68 weeks rather than 12 or 24 weeks.

During your titration period, your UK prescriber may recommend staying at a particular dose for an additional month if you're experiencing persistent side effects. This individualised approach, available through Cured Pharmacy's ongoing prescriber support, helps maximise treatment adherence. Research shows that patients who complete the full titration schedule and maintain the 2.4mg dose achieve significantly better long-term outcomes than those who discontinue early due to tolerability issues [3].

Each Wegovy pen is single-use and pre-filled with one week's dose. Store unused pens in the refrigerator between 2-8°C, though they can remain at room temperature (up to 30°C) for up to 28 days if needed. Always check the solution is clear and colourless before injecting — if it appears cloudy or discoloured, contact our pharmacy team immediately for a replacement.

The Four-Month Titration Period

Wegovy follows a structured dose escalation schedule designed to minimise gastrointestinal side effects whilst your body adjusts to semaglutide. You'll start at 0.25mg weekly for four weeks, then increase to 0.5mg, 1.0mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly [3]. This gradual titration is essential — patients who attempt to increase doses too quickly experience significantly higher rates of nausea and vomiting.

Common Side Effects and How to Manage Them

Practical strategies can significantly reduce gastrointestinal discomfort during your Wegovy treatment. Eat smaller, more frequent meals rather than three large meals daily. Avoid high-fat, greasy, or spicy foods, particularly in the 48 hours following your weekly injection. Stay well-hydrated, as adequate fluid intake helps prevent constipation and reduces nausea intensity. Many patients find that taking their injection in the evening, after eating dinner, minimises daytime nausea.

Serious side effects are rare but require immediate medical attention. Contact your GP or call 111 if you experience severe abdominal pain that doesn't resolve (potential pancreatitis), persistent vomiting preventing fluid intake (dehydration risk), or changes in vision. Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3]. Your UK prescriber screens for these conditions during your clinical assessment.

The STEP safety data, collected over 68 weeks from thousands of participants, showed that serious adverse events occurred at similar rates in semaglutide and placebo groups, with no unexpected safety signals [1][2]. Most patients who discontinue Wegovy do so in the first 12 weeks due to gastrointestinal side effects, not serious medical complications. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey to help you manage any side effects effectively.

Gastrointestinal Effects

Nausea is the most frequently reported side effect of Wegovy, affecting approximately 44% of patients in clinical trials, though it typically diminishes after the first 8-12 weeks as your body adjusts [1]. Other common gastrointestinal effects include diarrhoea (30%), constipation (24%), and vomiting (24%), with severity generally correlating to dose increases [3].

Who Can Use Wegovy: Eligibility Criteria in the UK

NICE guidelines and MHRA licensing specify that Wegovy is appropriate for adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [4]. Your UK prescriber calculates your BMI during the online consultation and assesses whether you meet prescribing criteria based on your medical history.

Wegovy is not suitable for everyone. Contraindications include pregnancy or breastfeeding, personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, diabetic retinopathy requiring active treatment, and severe gastrointestinal disease [3]. Patients with a history of pancreatitis require careful evaluation, as GLP-1 receptor agonists have been associated with acute pancreatitis in rare cases. Your prescriber reviews your complete medical history to identify any contraindications before approving your prescription.

Age also factors into eligibility — Wegovy is licensed for adults aged 18 and over, though prescribers may decline to prescribe to patients over 75 due to limited clinical trial data in this age group. If you're taking other medications, particularly insulin or sulphonylureas for diabetes, your prescriber will assess potential drug interactions and may need to adjust your existing treatment regimen. This comprehensive medical review, completed by UK-registered clinicians at Cured Pharmacy, ensures Wegovy is both safe and appropriate for your individual circumstances.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.